ACAD vs UNH

ACAD demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and profitability. The company trades below its Graham Number ($19.31) and intrinsic value estimate ($67.85), suggesting potential undervaluation on a defensive basis. However, recent earnings growth has reversed sharply, with year-over-year EPS declining by 83.7% and Q/Q growth at -66.7%, raising concerns about sustainability. Insider selling activity over the past six months, totaling $1.17M, adds bearish sentiment despite the strong F-Score. Analysts remain optimistic with a buy recommendation and a target price of $31.85, but the current price is still significantly below intrinsic value.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.